Usual Adult Dose for Hyperlipidemia:
75 mg subcutaneously every 2 weeks OR 300 mg subcutaneously once every 4 weeks
-For inadequate LDL-C (low density lipoprotein) response, may adjust dose to 150 mg subcutaneously every 2 weeks
Maximum dose: 150 mg subcutaneously every 2 weeks
Patients with Heterozygous Familial Hypercholesterolemia (HeFH) undergoing LDL Apheresis: 150 mg subcutaneously once every 2 weeks; dose may be administered without regard to the timing of apheresis
Comments:
-Assess LDL-C when clinically appropriate, the LDL-C lowering effect may be measured as early as 4 weeks after initiating therapy.
-In some patients, LDL-C can vary considerably during 4-week dosing intervals, therefore measure LDL-C just prior to the next scheduled dose.
-If LDL-C reduction is inadequate, consider adjusting dose to 150 mg every 2 weeks starting new dose on the next scheduled dosing date.
Uses:
-As an adjunct to diet, alone or in combination with other lipid-lowering therapies for the treatment of primary hyperlipidemia including HeFH to reduce LDL-C.
-To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
Usual Adult Dose for Heterozygous Familial Hypercholesterolemia:
75 mg subcutaneously every 2 weeks OR 300 mg subcutaneously once every 4 weeks
-For inadequate LDL-C (low density lipoprotein) response, may adjust dose to 150 mg subcutaneously every 2 weeks
Maximum dose: 150 mg subcutaneously every 2 weeks
Patients with Heterozygous Familial Hypercholesterolemia (HeFH) undergoing LDL Apheresis: 150 mg subcutaneously once every 2 weeks; dose may be administered without regard to the timing of apheresis
Comments:
-Assess LDL-C when clinically appropriate, the LDL-C lowering effect may be measured as early as 4 weeks after initiating therapy.
-In some patients, LDL-C can vary considerably during 4-week dosing intervals, therefore measure LDL-C just prior to the next scheduled dose.
-If LDL-C reduction is inadequate, consider adjusting dose to 150 mg every 2 weeks starting new dose on the next scheduled dosing date.
Uses:
-As an adjunct to diet, alone or in combination with other lipid-lowering therapies for the treatment of primary hyperlipidemia including HeFH to reduce LDL-C.
-To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
Usual Adult Dose for Cardiovascular Risk Reduction:
75 mg subcutaneously every 2 weeks OR 300 mg subcutaneously once every 4 weeks
-For inadequate LDL-C (low density lipoprotein) response, may adjust dose to 150 mg subcutaneously every 2 weeks
Maximum dose: 150 mg subcutaneously every 2 weeks
Patients with Heterozygous Familial Hypercholesterolemia (HeFH) undergoing LDL Apheresis: 150 mg subcutaneously once every 2 weeks; dose may be administered without regard to the timing of apheresis
Comments:
-Assess LDL-C when clinically appropriate, the LDL-C lowering effect may be measured as early as 4 weeks after initiating therapy.
-In some patients, LDL-C can vary considerably during 4-week dosing intervals, therefore measure LDL-C just prior to the next scheduled dose.
-If LDL-C reduction is inadequate, consider adjusting dose to 150 mg every 2 weeks starting new dose on the next scheduled dosing date.
Uses:
-As an adjunct to diet, alone or in combination with other lipid-lowering therapies for the treatment of primary hyperlipidemia including HeFH to reduce LDL-C.
-To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
Usual Adult Dose for Homozygous Familial Hypercholesterolemia:
150 mg subcutaneously once every 2 weeks
Comments:
-Assess LDL-C when clinically appropriate, the LDL-C lowering effect may be measured as early as 4 weeks after initiating therapy.
Uses:
-As an adjunct to other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH), to reduce low density lipoprotein cholesterol (LDL-C).
 Detailed Praluent dosage information
What happens if I miss a dose?
Give an injection within 7 days after the missed dose. Then give the next injection 2 to 4 weeks after the missed dose was due, to put you back on your regular injection schedule.
If you are more than 7 days late for an injection:
If you inject every 2 weeks, skip the missed dose and use your next dose at the regular time.
If you inject every 4 weeks, start a new schedule based on the date you used the missed injection.
Do not use two doses at one time.
What happens if I overdose?
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
